Big pharma companies need to buy innovation, biotech companies are getting sky-high valuations, and 2018 is shaping up to be the second biggest M&A year for the sector on record.
Demand For Gene Therapies To Prompt Surge In Pharma M&A
Big pharma companies need to buy innovation, biotech companies are getting sky-high valuations, and 2018 is shaping up to be the second biggest M&A year for the sector on record.